AACR Apr 13, 2022 Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests Premium Apr 13, 2022 RACE for Children Act Spurs Pharma to Study Molecularly Informed Drugs in Pediatric Cancer Patients Premium Apr 13, 2022 MSK Researchers Testing if Chemo-Induced Hypermutated Colon Cancers Respond to BMS' Opdivo Apr 12, 2022 New Epigenomic Biomarker Could Predict CAR T-Cell Therapy Resistance in Advanced Childhood Leukemia Premium Apr 12, 2022 In Sixth Year, Project GENIE Diversifying, Integrating Local Ancestry and Enhancing Clinical Data Premium Apr 12, 2022 Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses Apr 11, 2022 Cancer Genomics Project in Southwestern American Indians Aims to Improve Research, Care Disparities Apr 11, 2022 Adding Genetic Information to PSA Improves Biomarker's Performance in Prostate Cancer Diagnosis Apr 11, 2022 UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study Apr 11, 2022 One-Third of KRAS-Mutant NSCLC Patients in Amgen's Lumakras Trial Alive After Two Years Premium Apr 10, 2022 Phylogenetic Analysis IDs Subset of De Novo Tumors Unrelated to Primary DCIS Premium Apr 10, 2022 AACR Data Show Donor NK Cells Plus Bispecific Antibody Could Benefit CD30-Positive Lymphoma Patients Premium Jul 30, 2021 Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer Premium May 24, 2021 OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients Premium Apr 23, 2021 Startup OncXerna Therapeutics Explores Tumor Microenvironment to Help Guide Cancer Treatment Premium Apr 19, 2021 Biodesix's Proteomic Method for Predicting Immunotherapy Response Advancing Toward Market Premium Apr 15, 2021 Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches Premium Apr 15, 2021 AACR Project GENIE Enables Analysis of Growing Actionability, Disparities in Precision Oncology Premium Apr 14, 2021 Tecentriq Response Analysis in MyPathway Study Bolsters Case for Higher TMB Cutoff Premium Apr 13, 2021 AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week: Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
